Study of the drug “Kapikor” influence on the endothelial dysfunction in rats with doxorubicin cardiomyopathy


  • I. A. Zupanets National University of Pharmacy, Ukraine
  • S. K. Shebeko National University of Pharmacy, Ukraine
  • I. A. Otrishko National University of Pharmacy, Ukraine



endothelial dysfunction, meldonium, gamma-butyrobetaine, doxorubicin cardiomyopathy


Topicality. An alternative solution in terms of modern anti-ischemic therapy optimization is a combination of metabolic and hemodynamic concepts – joint use of precursors and carnitine analogs – meldonium and gamma-butyrobetaine (GBB). Pharmacodynamic benefits of these substances combined use are characterized by synergetic phenomenon in the form of mutual potentiation of their effects, it is displayed in the drug “Kapikor”.

Aim. The aim of this work was the experimental study of the drug “Kapikor” on endothelial dysfunction in rats with doxorubicin cardiomyopathy.

Materials and methods. The drug “Kapikor” and its cardioprotective properties study was carried out on the model of doxorubicin cardiomyopathy (DCM) in 90 white nonlinear rats.

Results and discussion. At the conditions of doxorubicin cardiomyopathy development it was shown that the cardioprotective properties of the drug “Kapikor” course, which is associated with the presence of metabolic, endothelialprotective, anti-ischemic, antihypoxic, antioxidant and anticytolitic, preconditioning activity. According to the combination of studied parameters in this disease model “Kapikor” excels the objects of comparison Mildronat and GBB.

Conclusions. The combined use of GBB and meldonium in the composition of “Kapikor” provides its monocomponents mutual modifying influence on indicators characterizing the inflammatory and destructive, degenerative-dystrophic and ischemic nature of myocardial dystrophy flow and has general protective influence on the cardioprotective effect level of the drug.


1. World Health Statistics 2012(2012). Geneva: WHO, 176.

2. European Detailed Mortality Database (2015). WHO, Regional Office for Europe. Available at:

3. Eurostat regional yearbook 2012 (2012). Luxembourg: Office of the European Union, 213.

White, A. (2011). The state of men’s health in Europe: extended report. European Union : European Commission. 401.

Dolzhenko, M. N. (2012). Mistetstvo lіkuvannia, 2–3, 3–6.

Zhitnikova, L. M. (2012). Russkii meditcinskii zhurnal, 20 (4), 137–143.

Sergienko, I. V. (2005). Atmosphera. Kardiologiia, 2, 43–45.

Arutiunov, G. P. (2015). Terapevticheskie aspekty diagnostiki i lecheniia zabolevanii serdtca i sosudov. Moscow: GEOTAR–Media, 608.

Belenkova, Ju. N., Oganova, R. G. (2007). Kardiologiia. Klinicheskie rekomendatcii. Moscow: GEOTAR–Media, 640.

Kovalenko, V. N. (2009). Rukovodstvo po kardiologii. Kiev: Morion, 1348.

Stephanov, A. V. (2002). Doklinicheskie issledovaniia lekarstvennyh sredstv. Kiev: Avitcenna, 528.

Semenov, A. N. (2001). Izuchenie kardioprotektornyh svoistv nesteroidnyh protivovospalitelnyh sredstv v riadu proizvodnyh D–(+)–gliukozamina. Kupavna, 26.

Rebrova, O. Ju. (2006). Statisticheskii analiz meditcinskih dannyh. Primenenie paketa prikladnyh programm STATISTICA, 3–e izd. Moscow: MediaSfera, 312.

Sergienko, V. I. (2006). Matematicheskaia statistika v klinicheskih issledovaniiah. Moskow: GEOTAR–Media, 304.

Truhacheva, N. V. (2012). Matematicheskaia statistika v mediko–biologicheskih issledovaniiah s primeneniem paketa Statistica. Moscow: GEOTAR–Media, 379.





Pharmacology and biochemistry